Early onset imminent eclampsia with antiphospholipid antibody syndrome and recurrent epilepsy with HELLP syndrome

Authors

  • Ruby Bhatia Department of Gyneacology-Obstetrics, MMIMSR, Mullana, Ambala, Haryana
  • Yeso Ashwini Department of Gyneacology-Obstetrics, MMIMSR, Mullana, Ambala, Haryana
  • Mahak Singaal Department of Gyneacology-Obstetrics, MMIMSR, Mullana, Ambala, Haryana

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20262585

Keywords:

Early-onset pre-eclampsia, Eclampsia, Antiphospholipid antibody syndrome, Recurrent pregnancy loss, Seizure disorder, Levetiracetam, Medical termination of pregnancy, Uteroplacental insufficiency, Multidisciplinary obstetric care

Abstract

Early-onset pre-eclampsia and eclampsia superimposed on antiphospholipid antibody syndrome (APLA) and a pre-existing seizure disorder represent one of the most challenging constellations in contemporary obstetric practice. The convergence of these conditions demands coordinated multidisciplinary expertise and carries very high maternal and foetal morbidity and mortality with known case of epilepsy on treatment.We report a 28-year-old woman (G6P1L1A4) at 18–23 weeks of gestation who presented across three sequential hospital admissions between 18-23 weeks with recurrent eclamptic seizures, severe hypertension (180/100 mmHg), moderate-to-severe anaemia, bilateral uterine artery diastolic notching indicating uteroplacental insufficiency, and a prior caesarean scar. Despite optimisation of antihypertensive and antiepileptic therapy including intravenous levetiracetam loading, eclampsia remained refractory. Multidisciplinary evaluation encompassing obstetrics, neurology, nephrology, haematology, psychiatry, ophthalmology, and neonatology ultimately concluded that continuation of the pregnancy posed imminent and extreme risk to maternal life. Medical termination of pregnancy (MTP) was performed at 23 weeks.This case underscores the catastrophic potential of untreated APLA syndrome in a patient with recurrent pregnancy loss, the diagnostic challenge of eclampsia superimposed on known epilepsy, and the critical importance of multidisciplinary management, proactive social support, and comprehensive pre-conception counselling in high-risk obstetric populations.

 

References

Magee LA, Khalil A, von Dadelszen P. FIGO Initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1–33.

Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol. 2005;105(2):402-10.

Miyakis S, Lockshin MD, Atsumi T. International consensus statement on classification criteria for antiphospholipid syndrome. J Thromb Haemost. 2006;4(2):295-306.

Mak A, Cheung MWL, Cheak AAC, Ho RCM. Heparin and aspirin vs. aspirin alone in recurrent pregnancy loss with antiphospholipid antibodies: a meta-analysis. Rheumatology (Oxford). 2010;49(2):281-8.

Meador K, Reynolds MW, Crean S. Pregnancy outcomes in women with epilepsy: a systematic review. Epilepsy Res. 2008;81(1):1–13.

Government of India. The Medical Termination of Pregnancy (Amendment) Act, 2021. Gazette of India Extraordinary Part II – Section 1. 25 March 2021.

Rangel-Frausto MS. Discharge against medical advice: challenges and opportunities. Arch Med Res. 2015;46(4):322-5.

Thangaratinam S, Coomarasamy A, O'Mahony F, et al. Proteinuria as a predictor of complications of pre-eclampsia: systematic review. BMC Med. 2009;7:10.

Downloads

Published

2026-07-29

How to Cite

Bhatia, R., Ashwini, Y., & Singaal, M. (2026). Early onset imminent eclampsia with antiphospholipid antibody syndrome and recurrent epilepsy with HELLP syndrome. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 15(8), 3327–3330. https://doi.org/10.18203/2320-1770.ijrcog20262585

Issue

Section

Case Reports